Soleno Therapeutics (NASDAQ:SLNO) Stock Price Up 10% - Time to Buy?

Key Points

• Stock jumped ~10–12% intraday to around $33, driven by unusually heavy call buying (≈2,940 calls) but on thin share volume (~147,595 vs. average 1.59M), suggesting short‑term speculative pressure.
• Multiple securities class actions have been filed alleging Soleno concealed problems tied to the DCCR (VYKAT XR) launch, increasing potential litigation, settlement and regulatory risk.
• Analysts are mostly positive with a consensus rating of “Moderate Buy” and an average price target of $102, yet the stock trades below its 50‑day ($38.28) and 200‑day ($48.24) moving averages and has a high PE (~150), reflecting mixed fundamental signals.

Soleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report)'s stock price was up 10% during mid-day trading on Tuesday . The company traded as high as $32.81 and last traded at $33.48. Approximately 147,595 shares changed hands during mid-day trading, a decline of 91% from the average daily volume of 1,587,466 shares. The stock had previously closed at $30.44.

Trending Headlines about Soleno Therapeutics

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Unusually heavy call buying — investors purchased about 2,940 call options today (≈+49% vs. the average of 1,968), signaling short-term bullish speculative activity that likely contributed to the stock’s intraday rise.
• Negative Sentiment: A new securities class action has been filed against Soleno alleging claims for purchases during March 26, 2025–August 4, 2025; a formal complaint increases litigation exposure and potential future financial/settlement risk. SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Soleno Therapeutics, Inc. (SLNO)
• Negative Sentiment: Hagens Berman and other firms tie the suits to Soleno’s November 2025 disclosures about DCCR (VYKAT XR) launch disruptions — the substantive allegation (management concealed drug risks) amplifies reputational and regulatory scrutiny. Soleno Therapeutics (SLNO) Faces Securities Class Action Amid Hyperphagia Drug Launch Disruptions -- Hagens Berman
• Negative Sentiment: Multiple plaintiff firms (Rosen, Faruqi & Faruqi, Gross, Glancy, Portnoy, Levi & Korsinsky, etc.) are issuing investor alerts and May 5, 2026 lead‑plaintiff deadline reminders — increased publicity raises the chance of consolidated litigation and settlement pressure. ROSEN, A TOP RANKED LAW FIRM, Encourages Soleno Therapeutics Inc. Investors to Secure Counsel

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on SLNO shares. Robert W. Baird set a $107.00 price objective on Soleno Therapeutics in a research report on Tuesday, January 13th. Oppenheimer reduced their target price on shares of Soleno Therapeutics from $110.00 to $80.00 and set an "outperform" rating for the company in a report on Wednesday, March 18th. TD Cowen lowered their price target on shares of Soleno Therapeutics from $120.00 to $85.00 and set a "buy" rating on the stock in a report on Thursday, February 26th. Wells Fargo & Company cut their price objective on shares of Soleno Therapeutics from $114.00 to $110.00 and set an "overweight" rating on the stock in a research report on Friday, February 27th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Soleno Therapeutics in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $102.00.

Soleno Therapeutics Trading Up 12.2%

The company has a 50 day moving average of $38.28 and a two-hundred day moving average of $48.24. The stock has a market capitalization of $1.76 billion, a PE ratio of 150.40 and a beta of -3.16. The company has a debt-to-equity ratio of 0.11, a quick ratio of 5.55 and a current ratio of 5.80.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last issued its quarterly earnings results on Wednesday, February 25th. The company reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.16. The business had revenue of $91.73 million during the quarter, compared to analyst estimates of $88.55 million. Sell-side analysts predict that Soleno Therapeutics, Inc. will post -3.72 EPS for the current year.

Institutional Trading of Soleno Therapeutics

Several large investors have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Soleno Therapeutics by 1.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,360 shares of the company's stock worth $1,242,000 after buying an additional 189 shares during the period. Goldman Sachs Group Inc. grew its holdings in shares of Soleno Therapeutics by 50.9% during the first quarter. Goldman Sachs Group Inc. now owns 633,110 shares of the company's stock valued at $45,236,000 after buying an additional 213,667 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Soleno Therapeutics by 48.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 40,715 shares of the company's stock valued at $2,909,000 after acquiring an additional 13,211 shares during the period. Creative Planning acquired a new position in shares of Soleno Therapeutics in the 2nd quarter valued at $338,000. Finally, Swiss National Bank raised its stake in Soleno Therapeutics by 24.4% in the 2nd quarter. Swiss National Bank now owns 62,300 shares of the company's stock worth $5,219,000 after acquiring an additional 12,200 shares during the last quarter. Hedge funds and other institutional investors own 97.42% of the company's stock.

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company's scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company's lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.